FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3096518687> ?p ?o ?g. }

• W3096518687 endingPage "43" @default.
• W3096518687 startingPage "42" @default.
• W3096518687 abstract "Introduction: Outcome of patients (pts) with CD20-positive B-cell acute lymphoblastic leukemia (B-ALL) has significantly improved with hyper-CVAD (HCVAD) in combination with rituximab with 3-year OS 65% (Thomas et al Blood 2009). Ofatumumab is an anti-CD20 monoclonal antibody with higher capacity of promoting complement-dependent cytotoxicity compared to rituximab. The aim of this study is to compare the outcome of pts with CD20-positive B-ALL who received HCVAD plus ofatumumab (HCVAD-O) or HCVAD plus rituximab (HCVAD-R) therapy. Methods: We reviewed 69 adult pts with newly diagnosed, Philadelphia chromosome (Ph)-negative, CD20-positive B-ALL who were treated with HCVAD-O at our institution between 8/2011 and 5/2017. HCVAD therapy consisted of 4 alternating cycles of hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone, plus high-dose methotrexate (MTX) / cytarabine (AraC) with 8 intrathecal injections of MTX/AraC. Ofatumumab was administered at 300mg IV as first dose, and 2000mg IV subsequently. The maintenance phase consisted of 30 cycles of 6-MP, MTX, vincristine, and prednisone (POMP) with 4 intensification courses (high-dose MTX plus L-asparaginase and HCVAD+O) on courses 6-7 and 18-19. Overall survival (OS) was calculated from the start date of treatment to the date of death, or last follow-up. We performed a comparison of survival between pts treated with HCVAD-O and a cohort of 153 historical-control pts treated with HCVAD with or without rituximab between 11/2002 and 7/2012. Historical-control pts were treated with HCVAD alone (N=58) if CD20 expression was 1-19% or HCVAD-R (N=95) if CD20 expression was ≥20%. To adjust for baseline differences of pts characteristics between the cohorts, we performed inverse probability of treatment weighing (IPTW) using propensity scores calculated from pts baseline characteristics. Covariates for the calculation of propensity scores included age, performance status, white blood cell count at diagnosis, the positivity of CD20 expression and adverse-risk cytogenetics (KMT2A-rearrangement, complex karyotype or low-hypodiploidy / near triploidy). Results: The median follow-up for HCVAD-O cohort and historical-control cohort was 44 months (95% CI: 41-53) and 133 months (95% CI: 115-141), respectively. There was no difference in baseline characteristics between HCVAD-O cohort and historical-control cohort (Table 1). The 5-year OS rates were 65% and 51% in HCVAD-O cohort and historical-control cohort, respectively. With the IPTW analysis, the HCVAD-O regimen was associated with better outcome compared with the historical HCVAD/HCVAD-R regimen (HR, 0.74; 95% CI, 0.55-0.99, p = 0.047) (Figure 1). The treatment effect was similar regardless of the level of CD20 positivity, although not statistically significant among each subgroup (CD20 ≥20%, HR 0.73, 95% CI, 0.52-1.04, p = 0.09; CD20 1-19%, HR, 0.68; 95% CI, 0.39-1.20, p = 0.18). Conclusions: The combination of HCVAD plus ofatumumab is highly effective and seems to have offered better outcome than did HCVAD plus rituximab therapy in pts with Ph-negative CD20-positive B-ALL. Additional novel monoclonal/bispecific antibody constructs targeting CD19 and CD22 are expected to further improve the outcome. Disclosures Sasaki: Otsuka: Honoraria; Daiichi Sankyo: Consultancy; Pfizer Japan: Consultancy; Novartis: Consultancy, Research Funding. Konopleva:F. Hoffmann La-Roche: Consultancy, Research Funding; Reata Pharmaceutical Inc.;: Patents & Royalties: patents and royalties with patent US 7,795,305 B2 on CDDO-compounds and combination therapies, licensed to Reata Pharmaceutical; Rafael Pharmaceutical: Research Funding; Amgen: Consultancy; Forty-Seven: Consultancy, Research Funding; AstraZeneca: Research Funding; AbbVie: Consultancy, Research Funding; Agios: Research Funding; Ablynx: Research Funding; Cellectis: Research Funding; Genentech: Consultancy, Research Funding; Ascentage: Research Funding; Sanofi: Research Funding; Stemline Therapeutics: Consultancy, Research Funding; Eli Lilly: Research Funding; Kisoji: Consultancy; Calithera: Research Funding. Short:Takeda Oncology: Consultancy, Honoraria, Research Funding; Amgen: Honoraria; Astellas: Research Funding; AstraZeneca: Consultancy. Jain:Pfizer: Research Funding; Cellectis: Research Funding; Aprea Therapeutics: Research Funding; Servier: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; BeiGene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pharmacyclics: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Verastem: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; ADC Therapeutics: Research Funding; Adaptive Biotechnologies: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Genentech: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS: Research Funding; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Precision Bioscienes: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Incyte: Research Funding; Fate Therapeutics: Research Funding; TG Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees. Ravandi:Macrogenics: Research Funding; Astellas: Consultancy, Honoraria, Research Funding; Jazz Pharmaceuticals: Consultancy, Honoraria, Research Funding; AstraZeneca: Consultancy, Honoraria; Celgene: Consultancy, Honoraria; Amgen: Consultancy, Honoraria, Research Funding; Xencor: Consultancy, Honoraria, Research Funding; Orsenix: Consultancy, Honoraria, Research Funding; BMS: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria, Research Funding. Daver:Daiichi Sankyo: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Bristol-Myers Squibb: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Karyopharm: Research Funding; Servier: Research Funding; Genentech: Research Funding; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Astellas: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novimmune: Research Funding; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Trovagene: Research Funding; Fate Therapeutics: Research Funding; ImmunoGen: Research Funding; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Jazz: Consultancy, Membership on an entity's Board of Directors or advisory committees; Trillium: Consultancy, Membership on an entity's Board of Directors or advisory committees; Syndax: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees; KITE: Consultancy, Membership on an entity's Board of Directors or advisory committees; Agios: Consultancy, Membership on an entity's Board of Directors or advisory committees. Kadia:Genentech: Honoraria, Research Funding; Cyclacel: Research Funding; Pulmotec: Research Funding; Astellas: Research Funding; Novartis: Honoraria; Celgene: Research Funding; JAZZ: Honoraria, Research Funding; Amgen: Research Funding; BMS: Honoraria, Research Funding; Abbvie: Honoraria, Research Funding; Incyte: Research Funding; Ascentage: Research Funding; Cellenkos: Research Funding; Pfizer: Honoraria, Research Funding; Astra Zeneca: Research Funding. Alvarado:FibroGen: Research Funding; Daiichi-Sankyo: Research Funding; Jazz Pharmaceuticals: Research Funding; Sun Pharma: Research Funding; BerGenBio ASA: Research Funding; MEI Pharma: Research Funding; Tolero Pharmaceuticals: Research Funding; Astex Pharmaceuticals: Research Funding. DiNardo:Agios: Consultancy, Honoraria, Research Funding; AbbVie: Consultancy, Honoraria, Research Funding; Syros: Honoraria; Calithera: Research Funding; ImmuneOnc: Honoraria; Daiichi Sankyo: Consultancy, Honoraria, Research Funding; Novartis: Consultancy; Takeda: Honoraria; Notable Labs: Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Honoraria, Research Funding; MedImmune: Honoraria; Jazz: Honoraria. Issa:Novartis: Membership on an entity's Board of Directors or advisory committees; Syndax: Research Funding; Celegene: Research Funding. Pemmaraju:MustangBio: Honoraria; AbbVie: Honoraria, Research Funding; Pacylex Pharmaceuticals: Consultancy; LFB Biotechnologies: Honoraria; Daiichi Sankyo: Research Funding; Incyte Corporation: Honoraria; Stemline Therapeutics: Honoraria, Research Funding; SagerStrong Foundation: Other: Grant Support; Novartis: Honoraria, Research Funding; Affymetrix: Other: Grant Support, Research Funding; Plexxikon: Research Funding; Celgene: Honoraria; DAVA Oncology: Honoraria; Roche Diagnostics: Honoraria; Cellectis: Research Funding; Blueprint Medicines: Honoraria; Samus Therapeutics: Research Funding. Garcia-Manero:Astex Pharmaceuticals: Consultancy, Honoraria, Research Funding; Amphivena Therapeutics: Research Funding; Onconova: Research Funding; H3 Biomedicine: Research Funding; AbbVie: Honoraria, Research Funding; Novartis: Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Bristol-Myers Squibb: Consultancy, Research Funding; Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Acceleron Pharmaceuticals: Consultancy, Honoraria; Merck: Research Funding; Helsinn Therapeutics: Consultancy, Honoraria, Research Funding; Jazz Pharmaceuticals: Consultancy. Verstovsek:Incyte Corporation: Consultancy, Research Funding; Roche: Research Funding; NS Pharma: Research Funding; Gilead: Research Funding; Genentech: Research Funding; Novartis: Consultancy, Research Funding; ItalPharma: Research Funding; AstraZeneca: Research Funding; PharmaEssentia: Research Funding; CTI Biopharma Corp: Research Funding; Sierra Oncology: Consultancy, Research Funding; Promedior: Research Funding; Blueprint Medicines Corp: Research Funding; Protagonist Therapeutics: Research Funding; Celgene: Consultancy, Research Funding. Champlin:Johnson and Johnson: Consultancy; Actinium: Consultancy; DKMS America: Membership on an entity's Board of Directors or advisory committees; Genzyme: Speakers Bureau; Omeros: Consultancy; Takeda: Patents & Royalties; Cytonus: Consultancy. Khouri:Bristol Myers Squibb: Research Funding; Pfizer: Research Funding. Kebriaei:Novartis: Other: Served on advisory board; Pfizer: Other: Served on advisory board; Amgen: Other: Research Support; Ziopharm: Other: Research Support; Kite: Other: Served on advisory board; Jazz: Consultancy. O'Brien:Kite, Regeneron, Acerta: Research Funding; Gilead, Pharmacyclics, TG Therapeutics, Pfizer, Sunesis: Consultancy, Research Funding; Amgen, Astellas, Celgene, GlaxoSmithKline, Janssen Oncology, Aptose Biosciences Inc. Vaniam Group, AbbVie, Alexion, Verastem, Eisai, Juno Therapeutics, Vida Ventures: Consultancy. Kantarjian:Daiichi-Sankyo: Research Funding; Immunogen: Research Funding; Ariad: Research Funding; Novartis: Research Funding; BMS: Research Funding; Cyclacel: Research Funding; Agios: Honoraria, Research Funding; Jazz Pharma: Research Funding; Takeda: Honoraria; AbbVie: Honoraria, Research Funding; Actinium: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Research Funding; Astex: Research Funding; Pfizer: Honoraria, Research Funding. Jabbour:Pfizer: Other: Advisory role, Research Funding; Adaptive Biotechnologies: Other: Advisory role, Research Funding; BMS: Other: Advisory role, Research Funding; Genentech: Other: Advisory role, Research Funding; Takeda: Other: Advisory role, Research Funding; Amgen: Other: Advisory role, Research Funding; AbbVie: Other: Advisory role, Research Funding." @default.
• W3096518687 created "2020-11-09" @default.
• W3096518687 creator A5000750846 @default.
• W3096518687 creator A5004203354 @default.
• W3096518687 creator A5007688820 @default.
• W3096518687 creator A5010786159 @default.
• W3096518687 creator A5011548707 @default.
• W3096518687 creator A5020340537 @default.
• W3096518687 creator A5021380291 @default.
• W3096518687 creator A5022647201 @default.
• W3096518687 creator A5028591457 @default.
• W3096518687 creator A5029750735 @default.
• W3096518687 creator A5033737136 @default.
• W3096518687 creator A5035605515 @default.
• W3096518687 creator A5043364502 @default.
• W3096518687 creator A5046517633 @default.
• W3096518687 creator A5048913229 @default.
• W3096518687 creator A5049385583 @default.
• W3096518687 creator A5049448914 @default.
• W3096518687 creator A5051949215 @default.
• W3096518687 creator A5057822243 @default.
• W3096518687 creator A5059600583 @default.
• W3096518687 creator A5061026876 @default.
• W3096518687 creator A5069460930 @default.
• W3096518687 creator A5070065917 @default.
• W3096518687 creator A5085521139 @default.
• W3096518687 creator A5088307376 @default.
• W3096518687 creator A5088881526 @default.
• W3096518687 creator A5089295627 @default.
• W3096518687 creator A5090435894 @default.
• W3096518687 creator A5091492845 @default.
• W3096518687 date "2020-11-05" @default.
• W3096518687 modified "2023-10-18" @default.
• W3096518687 title "Comparison of Hyper-CVAD Plus Ofatumumab to Hyper-CVAD Plus Rituximab in Patients with Newly Diagnosed Philadelphia Chromosome-Negative CD20-Positive B-Cell Acute Lymphoblastic Leukemia: A Propensity Score Analysis" @default.
• W3096518687 doi "https://doi.org/10.1182/blood-2020-142121" @default.
• W3096518687 hasPublicationYear "2020" @default.
• W3096518687 type Work @default.
• W3096518687 sameAs 3096518687 @default.
• W3096518687 citedByCount "0" @default.
• W3096518687 crossrefType "journal-article" @default.
• W3096518687 hasAuthorship W3096518687A5000750846 @default.
• W3096518687 hasAuthorship W3096518687A5004203354 @default.
• W3096518687 hasAuthorship W3096518687A5007688820 @default.
• W3096518687 hasAuthorship W3096518687A5010786159 @default.
• W3096518687 hasAuthorship W3096518687A5011548707 @default.
• W3096518687 hasAuthorship W3096518687A5020340537 @default.
• W3096518687 hasAuthorship W3096518687A5021380291 @default.
• W3096518687 hasAuthorship W3096518687A5022647201 @default.
• W3096518687 hasAuthorship W3096518687A5028591457 @default.
• W3096518687 hasAuthorship W3096518687A5029750735 @default.
• W3096518687 hasAuthorship W3096518687A5033737136 @default.
• W3096518687 hasAuthorship W3096518687A5035605515 @default.
• W3096518687 hasAuthorship W3096518687A5043364502 @default.
• W3096518687 hasAuthorship W3096518687A5046517633 @default.
• W3096518687 hasAuthorship W3096518687A5048913229 @default.
• W3096518687 hasAuthorship W3096518687A5049385583 @default.
• W3096518687 hasAuthorship W3096518687A5049448914 @default.
• W3096518687 hasAuthorship W3096518687A5051949215 @default.
• W3096518687 hasAuthorship W3096518687A5057822243 @default.
• W3096518687 hasAuthorship W3096518687A5059600583 @default.
• W3096518687 hasAuthorship W3096518687A5061026876 @default.
• W3096518687 hasAuthorship W3096518687A5069460930 @default.
• W3096518687 hasAuthorship W3096518687A5070065917 @default.
• W3096518687 hasAuthorship W3096518687A5085521139 @default.
• W3096518687 hasAuthorship W3096518687A5088307376 @default.
• W3096518687 hasAuthorship W3096518687A5088881526 @default.
• W3096518687 hasAuthorship W3096518687A5089295627 @default.
• W3096518687 hasAuthorship W3096518687A5090435894 @default.
• W3096518687 hasAuthorship W3096518687A5091492845 @default.
• W3096518687 hasBestOaLocation W30965186871 @default.
• W3096518687 hasConcept C126322002 @default.
• W3096518687 hasConcept C143998085 @default.
• W3096518687 hasConcept C17923572 @default.
• W3096518687 hasConcept C18031839 @default.
• W3096518687 hasConcept C2778461978 @default.
• W3096518687 hasConcept C2778714382 @default.
• W3096518687 hasConcept C2779338263 @default.
• W3096518687 hasConcept C2780653079 @default.
• W3096518687 hasConcept C2909962599 @default.
• W3096518687 hasConcept C71924100 @default.
• W3096518687 hasConceptScore W3096518687C126322002 @default.
• W3096518687 hasConceptScore W3096518687C143998085 @default.
• W3096518687 hasConceptScore W3096518687C17923572 @default.
• W3096518687 hasConceptScore W3096518687C18031839 @default.
• W3096518687 hasConceptScore W3096518687C2778461978 @default.
• W3096518687 hasConceptScore W3096518687C2778714382 @default.
• W3096518687 hasConceptScore W3096518687C2779338263 @default.
• W3096518687 hasConceptScore W3096518687C2780653079 @default.
• W3096518687 hasConceptScore W3096518687C2909962599 @default.
• W3096518687 hasConceptScore W3096518687C71924100 @default.
• W3096518687 hasIssue "Supplement 1" @default.
• W3096518687 hasLocation W30965186871 @default.
• W3096518687 hasOpenAccess W3096518687 @default.
• W3096518687 hasPrimaryLocation W30965186871 @default.
• W3096518687 hasRelatedWork W1594284322 @default.
• W3096518687 hasRelatedWork W1721657566 @default.
• W3096518687 hasRelatedWork W2017136768 @default.
• W3096518687 hasRelatedWork W2126960075 @default.

• next